PTGX
Protagonist Therapeutics, Inc.91.54
-3.25-3.43%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
5.72BP/E (TTM)
138.70Basic EPS (TTM)
0.66Dividend Yield
0%Recent Filings
10-K
FY2025 results
Protagonist Therapeutics ended FY2025 with $646M in cash, up from $559M, funding a robust pipeline sans product revenue. Q4 saw rusfertide's NDA filing with Takeda after Phase 3 VERIFY success and $25M milestone; PN-881 dosed first patient in Phase 1, PN-477/PN-458 obesity candidates advanced to IND-enabling. R&D jumped 15% to $159M annually, driven by Q4 obesity/hepcidin acceleration, yet cash burn stayed controlled at $58M operating cash use. No debt; $646M runway extends years. Clinical delays could stall momentum.
8-K
Q4 loss, strong cash, pipeline advances
Protagonist Therapeutics reported Q4 and full-year 2025 results on February 25, 2026, posting a $44.4M quarterly net loss and $130.1M annual net loss, versus prior-year profits, as collaboration revenue plunged to $7.4M from $170.6M due to lumpy milestones. Cash swelled to $646M, funding operations through 2028. Rusfertide NDA submitted; ICOTYDE decision looms in 2026. Pipeline expands with obesity agonists.
8-K
Updated pipeline presentation out
Protagonist Therapeutics released an updated corporate presentation on January 12, 2026, highlighting icotrokinra's psoriasis NDA filed July 2025 and rusfertide's PV NDA submitted December 2025. Multiple Phase 3 readouts loom through 2028, alongside wholly-owned oral IL-17 and obesity assets advancing to clinic. Catalysts abound. Partnerships with JNJ and Takeda promise milestones and royalties.
10-Q
Q3 FY2025 results
Protagonist Therapeutics posted Q3 revenue of $4.7M, flat y/y from $4.7M, but YTD revenue plunged 85% to $38.6M from $263.8M after 2024's big Takeda upfront. Operating loss widened 12% y/y to $46.4M on 11% higher R&D spend ($40.0M), fueled by pre-clinical pushes for PN-881 and PN-477, while rusfertide costs eased post-VERIFY completion. Cash pile swelled to $678.8M, bolstered by $94.6M operating cash flow. No debt. Rusfertide NDA eyed by year-end. FDA disruptions pose review risks.
8-K
Q3 loss widens, cash strong
Protagonist Therapeutics reported Q3 2025 net loss of $39.3 million, up from $33.2 million last year, driven by higher R&D spend on discovery programs, yet cash pile hit $678.8 million for runway through 2028. Pipeline advances: icotrokinra NDAs filed with FDA/EMA, rusfertide Breakthrough Designation and NDA imminent, first PN-881 patient dosed. Cash fuels execution.
IPO
Employees
Sector
Industry
KALV
KalVista Pharmaceuticals, Inc.
15.90-1.00
LSTA
Lisata Therapeutics, Inc.
2.05+0.01
PKTX
ProtoKinetix, Inc.
0.00+0.00
PLRX
Pliant Therapeutics, Inc.
1.25+0.01
PPCB
Propanc Biopharma, Inc.
0.73-0.03
PRQR
ProQR Therapeutics N.V.
2.27-0.18
PTIX
Protagenic Therapeutics, Inc.
1.52-0.07
RAPT
RAPT Therapeutics, Inc.
34.03+0.81
VRTX
Vertex Pharmaceuticals Incorpor
454.96-0.75
VTVT
vTv Therapeutics Inc.
35.14+1.38